October 01, 2022
3 min watch
Save
VIDEO: Harrow CEO discusses Iheezo approval, fortified antibiotic
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video from Eyecelerator@AAO, Harrow CEO Mark L. Baum discusses the recent FDA approval of Iheezo for ocular surface anesthesia as well as a new refrigeration-stable fortified antibiotic.
The combination of tobramycin and vancomycin will allow ophthalmologists to stock a fortified antibiotic in their offices for in-office treatment, he said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Baum reports being CEO of Harrow.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.